{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:07Z","timestamp":1783344427294,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T16:11:22Z","timestamp":1718467882000},"page":"724-731.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed\/Refractory Hodgkin Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-3274","authenticated-orcid":false,"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Puverel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Nikolaenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacolle","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-8603","authenticated-orcid":false,"given":"Saro","family":"Armenian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.017_bib0001","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.017_bib0002","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.017_bib0003","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates","volume":"281","author":"Sutherland","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2024.05.017_bib0004","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0005","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0006","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3109\/10428194.2012.666543","article-title":"Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure","volume":"53","author":"Nathwani","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.017_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.15742","article-title":"A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks","volume":"186","author":"Poston","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.05.017_bib0008","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","article-title":"Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance","volume":"10","author":"Lum","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.017_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0145-2126(95)00029-N","article-title":"Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias","volume":"19","author":"Slater","year":"1995","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2024.05.017_bib0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","article-title":"Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients","volume":"5","author":"Ozols","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.017_bib0011","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1992.10.10.1624","article-title":"Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance","volume":"10","author":"Yahanda","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.017_bib0012","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.05.017_bib0013","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182128","article-title":"Favezelimab in combination with pembrolizumab in patients with anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma: updated analysis of an open-label phase 1\/2 study","volume":"142","author":"Johnson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0015","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.017_bib0016","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-190753","article-title":"The combination of nivolumab and CC-486 Is active in Hodgkin lymphoma refractory to PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149675","article-title":"Ruxolitinib Plus Nivolumab in Patients with R\/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.017_bib0018","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3949\/ccjm.61.4.308","article-title":"Cyclosporine: mechanisms of action and toxicity","volume":"61","author":"Graham","year":"1994","journal-title":"Cleve Clin J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:41Z","timestamp":1729696241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S215226502400209X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed\/Refractory Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}